AR063790A1 - Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos - Google Patents
Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismosInfo
- Publication number
- AR063790A1 AR063790A1 ARP070105033A ARP070105033A AR063790A1 AR 063790 A1 AR063790 A1 AR 063790A1 AR P070105033 A ARP070105033 A AR P070105033A AR P070105033 A ARP070105033 A AR P070105033A AR 063790 A1 AR063790 A1 AR 063790A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- halo
- alkyl
- benzene ring
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) en el que: R es hidrógeno o R tornado junto con R1 y el nitrógeno al que están unidos forman una pirrolidina opcionalmente condensada con un anillo bencénico o un anillo de piperidina opcionalmente condensada con un anillo bencénico, donde dicha pirrolidina, dicha pirrolidina condensada con un anido bencénico, dicha piperidina y dicha piperidina condensada con un anillo bencénico se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados cada uno independientemente de metilo, halo, -OH o C(O)-O-alquilo C1-4; R1 es: (a) alquilo C3-8, (b) alquenilo C3-8, (c) carbociclo C5-6 parcial o totalmente saturado opcionalmente condenando con un anillo bencénico, (d) heterociclo de 5 a 6 miembros, parcial o totalmente saturado, que contiene 1 a 2 heteroátomos seleccionados independientemente de O, S o N, opcionalmente condensado con un anillo bencénico o (e) alquilo C1-3 sustituido con un resto químico seleccionado del grupo que consiste en: (i) carbociclo C3-6 parcial o totalmente saturado, opcionalmente condensado con un anillo bencénico, (ii) alcoxi C1-4, (iii) heterociclo de 5 a 6 miembros, parcial o totalmente saturado, que contiene 1 a 2 heteroátomos seleccionados independientemente de O, S o N, opcionalmente condensado con un anillo bencénico, (iv) heteroarilo de 5 a 6 miembros, que contiene 1 a 3 heteroátomos seleccionados independientemente de O, S o N, opcionalmente condensado con un anillo bencénico, (v) fenilo opcionalmente condensado con un heterociclo de 5 a 6 miembros, que contiene 1 a 2 heteroátomos seleccionados independientemente de O, S o N, (vi) naftilo, (vii) fenoxi y (viii) 2-oxo-2,3-dihidrobenzimidazolilo, donde dichos sustituyentes (a) a (e) y dichos restos químicos (i) a (viii) están cada uno opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente de: hidroxilo, halo, metilo u HO-alquilo C1-3, R2a y R2b son cada uno hidrógeno; R3 es: hidrógeno, halo, alquilo C1-3, hidroxilo, alcoxi C1-3 o benciloxi, R4 es: hidrógeno, halo, alquilo C1-3, hidroxilo, alcoxi C1-3 o metilo fluorosustituido; V es nitrógeno o C-R5, donde R5 es: hidrógeno, halo, alquilo C1-3, hidroxilo, alcoxi C1-3, metilo fluorosustituido o benciloxi; R6 es: hidrógeno, alquilo C1-3, hidroxilo, alcoxi C1-3 o halo; R7 es -C(O)NH2, -NHSO2-alquilo C1-4 o 1H-1,2,4-triazol-5-ilo y R8 es hidrógeno, flúor u -OH o R7 es: hidrógeno, flúor u -OH y R8 es: -C(O)NH2. -NHSO2alquilo C1-4 o 1H-1,2,4-triazol-5-ilo; R9 es: hidrógeno, hidroxilo, alquilo C1-3; metilo fluorosustituido, alcoxi C1-3 o halo y W es C-R10 y X es nitrógeno, o W es nitrógeno y X es C-R11, o W es C-R10 y X es C-R11, donde R10 es: hidrógeno, alquilo C1-3, hidroxilo, alcoxi C1-3, metilo fluorosustituido, ciano o halo y R11 es: hidrógeno, alquilo C1-3, hidroxilo, alcoxi C1-3 o halo; una sal farmacéuticamente aceptable del mismo o un solvato o hidrato de dicho compuesto o dicha sal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86547906P | 2006-11-13 | 2006-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063790A1 true AR063790A1 (es) | 2009-02-18 |
Family
ID=39125086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105033A AR063790A1 (es) | 2006-11-13 | 2007-11-12 | Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos |
Country Status (16)
Country | Link |
---|---|
US (1) | US7615651B2 (es) |
EP (1) | EP2084127A1 (es) |
JP (1) | JP2010509392A (es) |
KR (1) | KR20090064478A (es) |
CN (1) | CN101583593A (es) |
AR (1) | AR063790A1 (es) |
AU (1) | AU2007320906A1 (es) |
CA (1) | CA2669311C (es) |
CL (1) | CL2007003198A1 (es) |
IL (1) | IL198236A0 (es) |
MX (1) | MX2009004314A (es) |
NO (1) | NO20091649L (es) |
PE (1) | PE20081116A1 (es) |
TW (1) | TW200826927A (es) |
UY (1) | UY30706A1 (es) |
WO (1) | WO2008059335A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980151A (zh) | 2006-08-09 | 2014-08-13 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
JP2010527980A (ja) | 2007-05-22 | 2010-08-19 | プロシディオン・リミテッド | 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009030962A1 (en) * | 2007-09-07 | 2009-03-12 | Prosidion Limited | Bicyclic aryl and heteroaryl receptor modulators |
AR089771A1 (es) * | 2012-01-31 | 2014-09-17 | Lilly Co Eli | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
JP6254163B2 (ja) * | 2012-08-16 | 2017-12-27 | ザ スクリプス リサーチ インスティテュート | 新規カッパオピオイドリガンド |
WO2015162516A1 (en) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
CA3024556A1 (en) * | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
US5239084A (en) * | 1990-06-29 | 1993-08-24 | Hoffmann-La Roche Inc. | Substituted aminoalkyl biphenyl compounds |
CA2044533A1 (en) * | 1990-06-29 | 1991-12-30 | Philippe Guerry | Substituted aminoalkylbiphenyl derivatives |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
CA2098167C (en) | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
GB2276163A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Pyridine compounds. |
TW438774B (en) * | 1993-07-14 | 2001-06-07 | Hoffmann La Roche | Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines |
TW381025B (en) | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
DE4435477A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
RO118715B1 (ro) | 1994-10-27 | 2003-09-30 | Janssen Pharmaceutica Nv | Inhibitori ai sintezei apolipoproteinei-b |
US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
WO1997023212A1 (en) | 1995-12-21 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS |
WO1998028269A1 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
AU6645998A (en) | 1996-12-23 | 1998-07-17 | Du Pont Pharmaceuticals Company | Oxygen or sulfur containing heteroaromatics as factor xa inhibitors |
KR20010013977A (ko) | 1997-06-19 | 2001-02-26 | 블레어 큐. 퍼거슨 | 중성 p1 특이성 기를 갖는 인자 xa의 억제제 |
US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
AU7976998A (en) | 1997-06-19 | 1999-01-04 | Du Pont Merck Pharmaceutical Company, The | (amidino)6-membered aromatics as factor xa inhibitors |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
EP1042299A1 (en) | 1997-12-22 | 2000-10-11 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
KR100652994B1 (ko) | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
DK1140941T3 (da) * | 1998-12-23 | 2005-02-14 | Bristol Myers Squibb Pharma Co | Nitrogenholdige heterobicykliske forbindelser som faktor Xa-inhibitorer |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
EP1150948A1 (en) * | 1999-02-11 | 2001-11-07 | Cor Therapeutics, Inc. | ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa |
US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
JP4723706B2 (ja) * | 1999-09-02 | 2011-07-13 | トヨタ自動車株式会社 | 車両用電気制御システム |
NZ517829A (en) | 1999-09-17 | 2004-12-24 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
US6329527B1 (en) * | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
US6407256B1 (en) * | 1999-11-03 | 2002-06-18 | Bristol Myers Squibb Co | Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors |
KR20020070385A (ko) | 2000-01-29 | 2002-09-06 | 주식회사 엘지씨아이 | 아릴-아미딘을 가진 팩터 Xa 억제제와 그의 유도체, 및그의 프로드럭 |
AU2001234420A1 (en) * | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
DE10008329A1 (de) | 2000-02-23 | 2001-08-30 | Merck Patent Gmbh | Aminosulfonylbiphenylderivate |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
JP2004501913A (ja) * | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
DE10035144A1 (de) | 2000-07-19 | 2002-01-31 | Merck Patent Gmbh | Cyclische Aminosäurederivate |
CA2431800C (en) | 2000-12-14 | 2014-07-08 | Amylin Pharmaceuticals, Inc. | Peptide yy and peptide yy agonists for treatment of metabolic disorders |
US6924291B2 (en) | 2001-01-23 | 2005-08-02 | Merck & Co., Inc. | Process for making spiro isobenzofuranone compounds |
GB0106586D0 (en) | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
ATE284872T1 (de) | 2001-03-22 | 2005-01-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung |
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
AU2002307839B2 (en) | 2001-06-28 | 2006-03-16 | Zoetis P Llc | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
WO2003027637A2 (en) | 2001-09-24 | 2003-04-03 | Oregon Health And Science University | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
RU2304580C2 (ru) | 2002-07-29 | 2007-08-20 | Ф.Хоффманн-Ля Рош Аг | Новые бензодиоксолы |
WO2004011427A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
ES2294330T3 (es) | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
CA2499690C (en) * | 2002-09-19 | 2011-05-24 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonist |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
BRPI0408332A (pt) * | 2003-03-14 | 2006-03-21 | Ono Pharmaceutical Co | derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
CA2533594C (en) | 2003-07-23 | 2013-04-02 | Synta Pharmaceuticals, Corp. | Compounds for inflammation and immune-related uses |
GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
US7151097B2 (en) | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
DE602004027301D1 (de) | 2003-12-22 | 2010-07-01 | Merck Sharp & Dohme | Alpha-hydroxyamide als bradykininantagonisten oder inverse agonisten |
KR100799802B1 (ko) | 2004-02-04 | 2008-01-31 | 화이자 프로덕츠 인크. | 치환된 퀴놀린 화합물 |
EP1735268B1 (en) * | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
US20050245543A1 (en) | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
DE102004023522A1 (de) * | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Substituierte Cyclohexyl-1,4-diamin-Derivate |
BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
EP1761516B1 (de) | 2004-06-25 | 2007-11-28 | Basf Aktiengesellschaft | 2, 4, 5, 6-substituierte pyridine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen |
CN103980151A (zh) * | 2006-08-09 | 2014-08-13 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
-
2007
- 2007-11-01 WO PCT/IB2007/003393 patent/WO2008059335A1/en active Application Filing
- 2007-11-01 AU AU2007320906A patent/AU2007320906A1/en not_active Abandoned
- 2007-11-01 KR KR1020097009717A patent/KR20090064478A/ko not_active Application Discontinuation
- 2007-11-01 JP JP2009536810A patent/JP2010509392A/ja active Pending
- 2007-11-01 MX MX2009004314A patent/MX2009004314A/es not_active Application Discontinuation
- 2007-11-01 CA CA2669311A patent/CA2669311C/en not_active Expired - Fee Related
- 2007-11-01 CN CNA2007800498176A patent/CN101583593A/zh active Pending
- 2007-11-01 EP EP07825615A patent/EP2084127A1/en not_active Withdrawn
- 2007-11-06 CL CL200703198A patent/CL2007003198A1/es unknown
- 2007-11-09 UY UY30706A patent/UY30706A1/es not_active Application Discontinuation
- 2007-11-12 PE PE2007001552A patent/PE20081116A1/es not_active Application Discontinuation
- 2007-11-12 AR ARP070105033A patent/AR063790A1/es unknown
- 2007-11-12 TW TW096142671A patent/TW200826927A/zh unknown
- 2007-11-13 US US11/938,821 patent/US7615651B2/en not_active Expired - Fee Related
-
2009
- 2009-04-20 IL IL198236A patent/IL198236A0/en unknown
- 2009-04-24 NO NO20091649A patent/NO20091649L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US7615651B2 (en) | 2009-11-10 |
PE20081116A1 (es) | 2008-09-07 |
CA2669311C (en) | 2011-09-20 |
CA2669311A1 (en) | 2008-05-22 |
CL2007003198A1 (es) | 2008-02-15 |
KR20090064478A (ko) | 2009-06-18 |
WO2008059335A1 (en) | 2008-05-22 |
NO20091649L (no) | 2009-05-20 |
TW200826927A (en) | 2008-07-01 |
AU2007320906A1 (en) | 2008-05-22 |
JP2010509392A (ja) | 2010-03-25 |
UY30706A1 (es) | 2008-07-03 |
IL198236A0 (en) | 2009-12-24 |
US20080167371A1 (en) | 2008-07-10 |
MX2009004314A (es) | 2009-05-05 |
EP2084127A1 (en) | 2009-08-05 |
CN101583593A (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063790A1 (es) | Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos | |
AR057106A2 (es) | USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS | |
PE20230820A1 (es) | Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead | |
ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
AR041303A1 (es) | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4" | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR045747A1 (es) | Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores | |
CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
AR070361A1 (es) | Compuestos heterociclicos antiviricos | |
AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
NO20074763L (no) | (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi | |
AR063805A1 (es) | Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas. | |
AR058928A1 (es) | Piperazinas y piperidinas como potenciadoras de mglur5. usos y composiciones farmaceuticas. | |
PE20090549A1 (es) | Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |